Scratchpad

[creede]

CSBR – some DD…

( I bought 40K this am at 15cents… and will be looking to add on dips)

- Clean OTCBB reporting shell
- Last 10Q shows O/S of 17M…. A/S of 50M
---------------------------------------------------------------------
Very recent 8Ks:
STOCK SALE: Our Profile List stock Champions Sports, Inc., (OTCBB: CSBR 0.055 x 0.07) issued two 8K’s announcing stock sales to two doctors:

8K - On January 5, 2007, the Registrant agreed to issue 7,000,000 shares of common stock to Dr. David Sidransky, an individual investor, for an aggregate purchase price of $28,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.

8K - On January 3, 2007, the Registrant agreed to issue 2,500,000 shares of common stock to Dr. Manuel Hidalgo, an individual investor, for an aggregate purchase price of $10,000. These securities were issued pursuant to a privately negotiated transaction without an underwriter in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act.
-----------------------------------------------------------------

So these two guys got lots of shares at $0.004… who they are is very interesting:

Dr. David Sidransky:
Director (Ex. Vice-Chair), Imclone Systems – M-Cap $2.6 Billion, $31 PPS on NASDAQ

Also…
Director, Zila Inc, M-cap $120 Million, $2.25PPS on NASDAQ

Dr. Manuel Hidalgo
Director, Monogram Biosciences, M-cap $200 million, $1.50 PPS on NASDAQ

And now they together take control of this OTCBB trading shell.

M-cap approx - $4 Million [ 26.5M x 15c] (assumes adding their 9.5M shares to the O/S)

Hmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmmm
I wonder if this won’t eventually get uplisted to a big board with a JUICY project from these two fine doctors????
What’s your best guess?

Good Luck!
Treepeople
--------------------------

Ps. detailed Drs’ BIOS:

Dr. David Sidransky –
David Sidransky, M.D., has served as a director of the ImClone Systems, since January 2004. On June 15, 2005, Dr. Sidransky was named Vice Chairman of the Board of Directors. Dr. Sidransky is the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine. He is a founder of several private biotechnology companies and has served on scientific advisory boards of many private and publicly traded companies, including MedImmune Inc., Telik Inc., Roche, and Amgen Inc. Dr. Sidransky is also a director of Alfacell Inc. He was formerly on the Board of Scientific Counselors at the National Institute of Dental and Craniofacial Research and a member of the Recombinant DNA Advisory Committee at the National Institute of Health. Dr. Sidransky serves on numerous editorial boards and is Senior Editor of Clinical Cancer Research. In addition, he is a Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine. He has over 250 peer-reviewed publications, and has contributed more than 40 cancer reviews and chapters and also has numerous issued biotechnology patents. He has been the recipient of many awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relati advertisement.

Manuel Hidalgo, MD, PhD is an Associate Professor of Oncology and Co-Director of the Drug Development Program at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer in patients with solid tumors. His research focuses on optimizing the clinical development of novel treatments by measuring target receptor and molecular anomalies, as well as analyzing biological activity in the tumor and normal tissues of patients treated with specific therapies.